CLINICAL TRIALS PROFILE FOR PHENERGAN VC
✉ Email this page to a colleague
All Clinical Trials for PHENERGAN VC
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00147680 ↗ | Uterine Papillary Serous Cancer (UPSC) Trial | Completed | Queensland Centre for Gynaecological Cancer | Phase 2 | 2004-09-01 | This study will be an open, non-randomised, clinical phase 2 trial, which will involve 30 women diagnosed with uterine papillary serous cancer. The researchers will investigate the effect of four cycles of paclitaxel/carboplatin, followed by whole pelvic external beam radiotherapy to a standard pelvis field (50.4 Gy) with or without a para-aortic boost with respect to the safety and efficacy of treatment, and patterns of recurrence. |
NCT00426491 ↗ | Misoprostol for Non-Viable Pregnancies | Completed | Madigan Army Medical Center | Phase 3 | 1999-03-01 | The purpose of this study is to examine the effectiveness of Misoprostol (Cytotec; GD Searle and Co., Chicago, IL) for the management of non-viable first trimester pregnancies. Specifically, Misoprostol (15-S-15-methyl PGE1) will be compared to a placebo with expectant management in who have documented non-viable gestations. We will examine the following outcome variables: time to resolution, number of patients requiring dilation and curettage, change in hematocrit, cost to the institution, patient satisfaction, and reported side effects. |
NCT00541671 ↗ | Prevention of Narcotic-Induced Nausea | Terminated | Christiana Care Health Services | N/A | 2007-02-01 | We are doing this study to find out if extra medicine is needed to avoid the chance of nausea sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). Some doctors always give medicine to prevent the possible side effect of nausea, while others do not. We are looking to see if this extra medicine is helpful in preventing nausea. The goal is to screen all patients with pain and enroll enough subjects to reach our goal of 164 evaluable study participants. |
NCT00895531 ↗ | Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement | Terminated | EKR Therapeutics, Inc | Phase 4 | 2009-12-01 | The investigators hypothesize that patients who receive a femoral catheter with low dose epidural Depodur will experience comparable or superior pain relief than those who receive both femoral and sciatic catheters. In addition, the investigators hypothesize that the one catheter will be less time consuming to place and facilitate early ambulation of the patient. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PHENERGAN VC
Condition Name
Clinical Trial Locations for PHENERGAN VC
Trials by Country
Clinical Trial Progress for PHENERGAN VC
Clinical Trial Phase
Clinical Trial Sponsors for PHENERGAN VC
Sponsor Name